https://www.cbc.ca/player/play/2266896963696

https://www.wsws.org/en/articl....es/2023/09/30/cery-s

https://librti.com/view-video/....canada-s-dark-secret

n 2011, The Paul & Daisy Soros Fellowships for New Americans awarded Ramaswamy a post-graduate fellowship.
Controversy erupted over Ramaswamy’s alleged payoff of a Wikipedia editor to remove Soros connection from his Wikipedia page.
Former pharma exec and newfound anti-ESG crusader has substantial ties to China, the Covid industrial complex, Pfizer, Soros inc, and a track record of business calamities.
However, he was inducted as a Young Global Leader of the WEF, Class of 2021.
His post graduate scholarship to Yale law school was not paid for by George Soros and was paid instead by a foundation controlled by Soros’ elder brother, Paul Soros.
Ramaswamy had a far worse connection to COVID-19 mRNA vaccine technology, holding patents for nano-vaccines, Ramaswamy’s former company Genevant Sciences, a portfolion company of Roivant Sciences, is suing Pfizer and Moderna, claiming patent infringement on enabling delivery on the mRNA spike proteins to cells, that Ramaswamy’s company claims to have invented.
In 2021, Ramaswamy’s company sought to nationalize private health records to create a database of COVID-19 status, without patient consent, to cash in and profit on the C-19 Pandemic.

wikispooks .com /wiki /Vivek_Ramaswamy

In case you didn’t know about Vivek’s company Genevant….

‘Our unique capabilities…
Companies in the nucleic acid space typically work with only a singular modality, such as mRNA, siRNA or gene editors. Our multiple platforms provide the ability to exploit multiple constructs, and our technology is validated by the field-based licenses that we have granted to industry leaders.’
‘Genevant’s scientific leadership has pioneered Lipid Nanoparticle (LNP) nucleic acid delivery for 20+ years. With our proprietary advantages, LNPs can provide both optimal uptake into desired cells and efficient release, resulting in functional delivery of nucleic acid payloads to target tissues. Our LNP platform, the delivery technology behind the first and only siRNA-LNP product to achieve regulatory approval (Alnylam’s ONPATTRO®), also enables a wide array of mRNA-based applications, including vaccines, therapeutic protein production, and gene editing.’

www. genevant. com/ our-technology/